Human urotensin II and metabolic syndrome

Vascular Disease Prevention

Volumn 3, Issue 2, 2006, Pages 91-98

  Watanabe, Takuya ^a   Kanome, Tomoko ^a   Suguro, Toshiaki ^a   Miyazaki, Akira ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Coronary artery disease; Diabetes mellitus; Hyperlipidemia; Hypertension; Metabolic syndrome; Obesity; Urotensin II

Indexed keywords

1 (3 CARBAMIMIDOYLBENZYL) 4 METHYL 1H INDOL 2 CARBOXYLIC ACID (NAPHTHALEN 1 YLMETHYL)AMIDE; 1 [2 (4 BENZYL 4 HYDROXYPIPERIDIN 1 YL)ETHYL] 3 (2 METHYLQUINOLIN 4 YL)UREA SULPHATE; 2,6 DICHLORO N [4 CHLORO 3 [[2 (DIMETHYLAMINO)ETHYL]OXY]PHENYL] 4 (TRIFLUOROMETHYL)BENZENESULPHONAMIDE; 4 AMINOQUINOLINE; ACT 058362; ACYL COENZYME A; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BETA [2 NAPHTHYL] DEXTRO ALANYL CYCLIC(CYSTEINYLTRYROSYL DEXTRO TRYPTOPHANYLORNITHYLVALYLCYSTEINYL) BETA[2 NAPHTHYL] DEXTRO ALANINAMIDE; BIM 23127; GLUCOSE; HYDROGEN PEROXIDE; INSULIN; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN; NEUROPEPTIDE RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; S 6716; SB 611812; SEROTONIN; UNCLASSIFIED DRUG; URANTIDE; UROTENSIN II; UROTENSIN RECEPTOR; UROTENSIN RECEPTOR BLOCKING AGENT;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BODY WEIGHT; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; FOOD INTAKE; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RELEASE; LIPID METABOLISM; MACROPHAGE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER; STRESS; UPREGULATION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 33646573374     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/156727006776819396     Document Type: Review

References (88)

1. Douglas SA, Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 2000; 10: 229-37.
2. Russell FD, Kearns P, Toth I, Molenaar P. Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro. J Pharmacol Exp Ther 2004; 310: 209-14.
3. Douglas SA, Ohlstein EH. Urotensin receptors. In: Girdalstone D, Ed, The IUPHAR compendium of receptor characterization and classification. London, IUPHAR Media, 2000; 365-72.
4. Maguire JJ, Davenport AP. Is urotensin-II the new endothelin? Br J Pharmacol 2002; 137: 579-88.
5. Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, Davenport AP. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 2004; 25: 1767-74.
6. Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004; 176: 117-23.
7. Richards AM, Charles C. Urotensin II in the cardiovascular system. Peptides 2004; 25: 1795-802.
8. Russell FD, Meyers D, Galbraith AJ, et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003; 285: 1576-81.
9. Birker-Robaczewska M, Boukhadra C, Studer R, Mueller C, Binkert C, Nayler O. The expression of urotensin II receptor (U2R) is up-regulated by interferon-g. J Recept Signal Transduct Res 2003; 23: 289-305.
10. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002; 359: 1990-7.
11. Ames RS, Sarau HM, Douglas SA, et al. Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282-6.
12. Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004; 22: 1341-4.
13. Heringlake M, Kox T, Uzun O, et al. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 2004; 121: 129-36.
14. Lapp H, Boerrigter G, Costello-Boerrigter LC, et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 2004; 94: 93-7.
15. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation 2002; 106: 2877-80.
16. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 2003; 104: 1-5.
17. Totsune K, Takahashi K, Arihara Z, et al. Role of urotensin II in patients on dialysis. Lancet 2001; 358: 810-1.
18. Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 2002; 37: 767-72.
19. Balat O, Aksoy F, Kutlar I, et al. Increased plasma levels of Urotensin-II in preeclampsia-eclampsia: a new mediator in pathogenesis? Eur J Obstet Gynecol Reprod Biol 2005; 120: 33-8.
20. Thanassoulis G, Huyhn T, Giaid A. Urotensin II and cardiovascular diseases. Peptides 2004; 25: 1789-94.
21. Behm DJ, Harrison SM, Douglas SA, et al. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br J Pharmacol 2003; 139: 464-72.
22. Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 2001; 132: 5-9.
23. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000; 131: 441-6.
24. Bennett RT, Jones RD, Morice AH, Smith CFC, Cowen ME. Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries. Thorax 2004; 59: 401-7.
25. Camarda V, Rizzi A, Calo G, et al. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn-Schmiedeberg's Arch Pharmacol 2002; 365: 141-9.
26. Hillier C, Berry C, Petrie MC, et al. Effects of urotensin II in human arteries and veins of varying caliber. Circulation 2001; 103: 1378-81.
27. Stirrat A, Gallagher M, Douglas SA, et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001; 280: H925-8.
28. MacLean MR, Alexander D, Douglas SA, et al. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 2000; 130: 201-4.
29. Russell FD. Emerging roles of urotensin-II in cardiovascular disease. Pharmacol Ther 2004; 103: 223-43.
30. Bohm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002; 135: 25-7.
31. Wilkinson IB, Affolter JT, de Haas SL, et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovas Res 2002; 53: 341-7.
32. Giebing G, Tolle M, Jurgensen J, et al. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circ Res 2005; 97: 707-15.
33. Opgaard OS, Nothacker HP, Ehlert FJ, Krause DN. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 2000; 406: 265-71.
34. Tasaki K, Hori M, Ozaki H, Karaki H, Wakabayashi I. Mechanism of human urotensin II-induced contraction in rat aorta. J Pharmacol Sci 2004; 94: 376-83.
35. Rossowski WJ, Cheng BL, Taylor JE, Datta R, Coy DH. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol 2002; 438: 159-70.
36. Sauzeau V, Mellionnec EL, Bertoglio J, Scalbert E, Pacaud P, Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001; 88: 1102-4.
37. Behm DJ, Doe CP, Douglas SA, et al. Urotensin-II: a novel systemic hypertensive factor in the cat. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 274-80.
38. Sondermeijer B, Kompa A, Komesaroff P, Krum H. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 2005; 18: 1195-9.
39. Lin Y, Tsuchihashi T, Matsumura K, Abe I, Iida M. Central cardiovascular action of urotensin II in conscious rats. J Hypertens 2003; 21: 159-65.
40. Lin Y, Tsuchihashi T, Matsumura K, et al. Central cardiovascular action of urotensin II in spontaneously hypertensive rats. Hypertens Res 2003; 26: 839-45.
41. Watson AMD, Lambert GW, Smith KJ, May CN. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 2003; 42: 373-9.
42. Lu Y, Zou CJ, Huang DW, Tang CS. Cardiovascular effects of urotensin II in different brain areas. Peptides 2002; 23: 1631-5.
43. Song W, Ashton N, Balment RJ. A radioimmunoassay to detect urotensin II in the plasma of rat models of hypertension. J Physiol 2002; 544P: S024.
44. Thompson JP, Watt P, Sanghavi S, Strupish JW, Lambert DG. A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesth Analg 2003; 97: 1501-3.
45. Matsushita M, Shichiri M, Imai T, et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001; 19: 2185-90.
46. Liu GQ, Zeng ZP, Li HZ, et al. Expression of urotensin II and Gprotein coupled receptor 14 mRNA in human pheochromocytoma tissues. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2005; 27: 457-60.
47. Wenyi Z, Suzuki S, Hirai M, et al. Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia 2003; 46: 972-6.
48. Suzuki S, Wenyi Z, Hirai M, et al. Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japaneses. Peptides 2004; 25: 1803-8.
49. Totsune K, Takahashi K, Arihara Z, et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 2004; 25: 1809-14.
50. Langham RG, Kelly DJ, Gow RM, et al. Increased expression of urotensin II and urotensin II receptor in human diabetic nephrophathy. Am J Kidney Dis 2004; 44: 826-31.
51. Baron AD. Insulin resistance and vascular function. J Diabetes Complications 2002; 16: 92-102.
52. Silvestre RA, Rodriguez-Gallardo J, Egido EM, Marco J. Inhibition of insulin release by urotensin II - a study on the perfused rat pancreas. Horm Metab Res 2001; 33: 379-81.
53. Silvestre RA, Egido EM, Hernandez R, et al. Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur J Endocrinol 2004; 151: 803-9.
54. Maguire JJ, Kuc RE, Davenport AP. Vasoconstrictor activity of novel endothelin peptide, ET-1 (1-31), in human mammary and coronary arteries in vitro. Br J Pharmacol 2001; 134: 1360-6.
55. Sheridan MA, Plisetskaya EM, Bern HA, Gorbman A. Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. Gen Comp Endocrinol 1987; 66: 405-14.
56. Sheridan MA, Bern HA. Both somatostatin and the caudal neuropeptide, urotensin II, stimulate lipid mobilization from coho salmon liver incubated in vitro. Regul Pept 1986; 14: 333-44.
57. Takahashi K. Translational medicine in fish-derived peptides: from fish endocrinology to human physiology and diseases. Endocr J 2004; 51: 1-17.
58. Do-Rego JC, Chatenet D, Orta MH, et al. Behavioral effects of urotensin-II centrally administered in mice. Psychopharmacology (Berl) 2005; 14: 1-15.
59. Matsumoto Y, Abe M, Watanabe T, et al. Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents. Neurosci Lett 2004; 358: 99-102.
60. Naruse M, Nagata D, Tanabe A, Imaki T. Discovery and clinical implications of urotensin II. Nippon Rinsho 2004; 62 Suppl 9: 685-93.
61. Zhang Y, Li J, Cao J, et al. Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart Vessels 2002; 16: 64-8.
62. Kruger S, Graf J, Kunz D, et al. Urotensin II in patients with chronic heart failure. Eur J Heart Fail 2005; 7: 475-8.
63. Rdzanek A, Filipiak KJ, Karpinski G, Grabowski M, Opolski G. Exercise urotensin II dynamics in myocardial infarction survivors with and without hypertension. Int J Cardiol 2005; in press.
64. Hassan GS, Douglas SA, Ohlstein EH, Giaid A. Expression of urotensin-II in human coronary atherosclerosis. Peptides 2005; 26: 2464-72.
65. Katugampola SD, Kuc RE, Maguire JJ, Davenport. G-proteincoupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently deorphanized (urotensin-II, apelin and ghrelin) receptors. Clin Sci 2002; 103: 171S-5S.
66. Gray GA, Jones MR, Sharif I. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 2001; 69: 175-80.
67. Ishihata A, Ogaki T, Aita T, Katano Y. Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats. Eur J Pharmacol 2005; 523: 119-26.
68. Paysant J, Rupin A, Simonet S, Fabiani JN, Verbeuren TJ. Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II. Fundam Clin Pharmacol 2001; 15: 227-31.
69. Zhou P, Wu SY, Yu CF, et al. Effects of urotensin II on isolated rat hearts under normal perfusion and ischemia reperfusion. Sheng Li Xue Bao 2003; 55: 442-8.
70. Johns DG, Ao Z, Naselsky D, et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 2004; 370: 238-50.
71. Gendron G, Simard B, Gobeil F Jr, Sirois P, D'Orleans-Juste P, Regoli D. Human urotensin-II enhances plasma extravasation in specific vascular districts in Wistar rats. Can J Pysiol Pharmacol 2004; 82: 16-21.
72. Wang H, Mehta JL, Chen K, Zhang X, Li D. Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. J Cardiovasc Pharmacol 2004; 44: 577-81.
73. Watanabe T, Suguro T, Miyazaki A, et al. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 2005; 46: 738-44.
74. Hori M, Miyazaki A, Tamagawa H, et al. Up-regulation of acylcoenzyme A:cholesterol acyltransferase-1 by transforming growth factor-β1 during differentiation of human monocytes into macrophages. Biochem Biophys Res Commun 2004; 320: 501-5.
75. Suguro T, Watanabe T, Miyazaki A, et al. Serotonin acts as an upregulator of acyl-coenzyme A:cholesterol acyltransferase-1 in human monocyte-macrophages. Atherosclerosis 2005; in press.
76. Furukawa K, Hori M, Miyazaki A, et al. Adiponectin downregulates acyl-coenzyme A:cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 2004; 317: 831-6.
77. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 2001; 104: 16-8.
78. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 2001; 19: 2191-6.
79. Tamura K, Okazaki M, Tamura M, Isozumi K, Tasaki H, Nakashima Y. Urotensin II-induced activation of extracellular signalregulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci 2003; 72: 1049-60.
80. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 2005; 25: 519-25.
81. Rakowski E, Hassan GS, Dhanak D, Ohlstein EH, Douglas SA, Giaid A. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Moll Cell Cardiol 2005;39:785-91.
82. Douglas SA. Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? Curr Opin Pharmacol 2003; 3: 159-67.
83. Herold CL, Behm DJ, Buckley PT, Foley JJ, Douglas SA. The peptidic somatostatin analogs lanreotide, BIM-23127 and BIM-23042 are urotensin-II receptor ligands. Pharmacologist 2002; 44: 170-1.
84. Flohr S, Kurz M, Kostenis E, Brkovich A, Fournier A, Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 2002; 45: 1799-1805.
85. Clozel M, Binkert C, Birker-Robaczewska M, et al. Pharmacology of the urotensin-II receptor antagonist Palosuran (ACT-058362; 1-[2-(4-benzyl-4- hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 2004; 311: 204-12.
86. Clozel M, Hess P, Qiu C, Ding SS, Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 2005; in press.
87. Patacchini R, Santicioli P, Giuliani S, et al. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br J Pharmacol 2003; 140: 1155-8.
88. Dhanak D, Neeb MJ, Douglas SA. Urotensin-II receptor modulators. Annu Rep Med Chem 2003; 38: 99-110.